ASH 2018 | Outcomes of Hodgkin lymphoma patients who receive a second ASCT

Anna Sureda

Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the latest EBMT Lymphoma Working Party registry study. This evaluated the outcome of relapsed/refractory Hodgkin lymphoma patients who received a second autologous stem cell transplantation (ASCT2). Dr Sureda highlights the key messages from this study; the time between transplants is the most important predictive factor for long-term outcomes.

Share this video